Register for our free email digests:
Division of TiGenix NV
Latest From Nohla Therapeutics Inc.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.
The firm’s $260m Series D is the largest ever for biopharma in China and one of the biggest of the year worldwide; other notable financings go to Biohaven, Kymab and Magenta. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October through early December.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- TiGenix NV
- Senior Management
Eduardo Bravo, CEO
Claudia D'Augusta, PhD, CFO
Jose Luis Bravo, MD, PhD, VP, Global Medical, R&D
- Contact Info
Phone: (34) 91 804 92 64
Calle Marconi, 1
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.